Key facts
- It has raised $142.7M; the latest was Later Stage VC ($72.3M) in Mar 2026.
- Notable investors include HSG (Hong Kong), Qiming Venture Partners, OrbiMed, 5Y Capital, Lanchi Ventures — 26 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for QL Biopharm
- ·The full record, as it builds
Funding rounds
No funding rounds for QL Biopharm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QL Biopharm
Developer of recombinant protein drugs intended for the treatment of chronic metabolic diseases. The company offers the development of recombinant drugs to treat chronic metabolic diseases such as diabetes, obesity, and non-alcoholic fatty liver, enabling patients to improve the quality of their lives.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Website
- qlbiopharm.com/
- Ownership
- Privately Held (backing)
QL Biopharm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QL Biopharm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QL Biopharm in its N-PORT filings yet. We sweep new filings monthly.